Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
Viewpoints
Recent PCC Articles on Viewpoints
PCC
Original Research
Psychometric Properties of the Brazilian BSL-23
July 21, 2026
Findings support the validity, reliability, and structural stability of the Brazilian version of the Borderline Symptom List 23, expanding access to the assessment of borderline symptoms in Brazil.
Ramiro Figueiredo Catelan
,
Verena Barroso Bastos
,
Vinicius Guimarães Dornelles
, et al
PCC
Case Report
Modafinil for Hypoactive Delirium in the ICU
July 21, 2026
A 57-year-old woman with severe hypoactive delirium rapidly improved following a split-dosing strategy of modafinil.
Austin J. Eason
,
Noelle Dorvault
,
Hope Bentley
, et al
JCP
Original Research
Effects of Brexpiprazole on Functioning in Patients with Schizophrenia Who Have Hostility and Agitation Symptoms
July 20, 2026
This post hoc analysis showed that brexpiprazole may improve functioning in adults with schizophrenia, even if they have hostility and agitation symptoms.
Leslie Citrome
,
Anja Farovik
,
Anton M. Palma
, et al
Featured
Viewpoints Research
Clinical Overview
Does TMS Work for Depression? What Clinicians Should Know
July 17, 2026
An overview from Andrew Van Der Vaart, MD, on who responds to transcranial magnetic stimulation for depression, how it works, and how the standard, theta-burst, and SAINT protocols differ.
news
Psychedelics Are Advancing in GAD, but None Are Yet Approved
July 16, 2026
Two psychedelics show early GAD trial signals—DT120 and psilocybin—but no agent is approved for anxiety. Interpreting evidence by stage, not label, matters
PCC
Case Report
Mirtazapine-Induced Severe Hyponatremia
July 16, 2026
A 30-year-old man developed severe hyponatremia after starting mirtazapine, highlighting the importance of closely monitoring sodium levels when starting any antidepressant in patients already taking oxcarbazepine.
Nathan R. Luzum
,
Sahil Munjal
